Allarity Therapeutics, Inc. (ALLR)
$1.40+$0.02 (+1.45%) Today
Latest ALLR Insider Trades
Thomas Jensen - OfficerGrant or award200,000 sh
Thomas Jensen - Officer
Gerald W. McLaughlin - DirectorAllarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
No Form 4 activity for ALLR in the last 90 days.
6 Form 4 filings on record, the earliest from Oct 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Thomas Jensen - Officer | Grant or award | Common Stock | 200,000 | $0.00 | - | |
| Jesper Hoeiland - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Gerald W. McLaughlin - Director | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Jeremy R. Graff - Officer | Grant or award | Common Stock | 133,333 | $0.00 | - | |
| Jeremy R. Graff - Officer | Option exercise | Common Stock | 39,494 | - | - | |
| Jeremy R. Graff - Officer | Tax withholding / forfeiture | Common Stock | 14,613 | $1.58 | $23K | |
| Jeremy R. Graff - Officer | Option exercise | Restricted Stock Units | 39,494 | $0.00 | - | |
| Jeremy R. Graff - Officer | Grant or award | Common Stock | 118,483 | $2.11 | $250K |
Allarity Therapeutics, Inc. (ALLR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-14. The full record for ALLR runs to 6 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ALLR were filed in the last 90 days.
No insider sales of ALLR were filed in the last 90 days.
This page tracks ALLR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ALLR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
